FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2978346064> ?p ?o ?g. }

• W2978346064 abstract "Purpose: to evaluate the efficacy and safety of complex therapy of allergic conjunctivitis, including 0.2 % olopatodin. Patients and methods: In 40 allergic conjunctivitis (AK) patients were performed: assessment of the intensity of itching and tearing, as well as conjunctival hyperemia and folliculosis (points); Schirmer’s test (SHT; mm); tear film break up time (TFBUT, s); assessment of the lid wiper epitheliopathy symptom (LWES, points); calculation of the xerosis indicator (XI; points, according to Bijsterveld). In the 1 group (20 pollen AK patients) were given: 0.2 % olopatadine instillations (1 time per day); preservative free polyvinylpyrrolidone and polyvinyl alcohol fixed combination (2–3 times a day, from 7 days of therapy). Control points: 7 and 30 days of therapy. Patients of 2 group with pollen AK and chronic blepharitis (saprophytic flora and Demodex) were performed: 0.2 % olopatadine instillations (1 time per day); eyelid hygiene (poloxamer 188 and PEG-90 gel; 2 times per day); ointment containing gentamicin and dexamethasone (application on the eyelids margins, 2 times a day, 14 days); acaricidal gel (based on preparations of sulfur, sodium hyaluronate and aloe extract; 2 times a day, from 15 days of therapy); preservative free polyvinylpyrrolidone and polyvinyl alcohol fixed combination (2–3 times a day, from 15 days of therapy). Control points: 14 and 30 days of treatment. Statistical analysis included: calculation of an average and its standard deviation (М ± s); evaluation of reliability of differences in control points (Wilcoxon’s T-criterion; χ2 criterion). Statistically significant was p < 0,05. Results: Patients of both groups had good tolerability of the treatment; no significant systemic and local side effects of treatment were noted. In 1 group patients by the 7th and 30th day of therapy, a significant decrease in the severity of itching, tearing and conjunctival hyperemia was observed. By the 30th day of observation, the complete absence of itching was noted in 85 % of individuals, the absence of hyperemia — in 80 %. The rest of the observed severity of these signs did not exceed the level of one point, and their manifestations were non-permanent. Conjunctival follicular response significantly decreased by 30 days of observation. SHT showed a significant decrease in all control points, remaining within normal limits. Dynamics of TFBUT and XI by 7 days of therapy was unreliable. By the 30th day of treatment, there was a significant positive dynamics of TFBUT and XI, compared with the state before the therapy and 7 days of observation. At the same time, TFBUT and XI have reached values close to normal. In 2 group patients by the 14th and 30th day of therapy, a significant decrease in the severity of itching, tearing, hyperemia and follicular conjunctival reaction was recorded (by 1–2 points). The value of SHT showed a significant decrease in all control points (within the normal values of the indicator). By the 14th day of therapy, a significant decrease of LWES was noted; the NT and XI the dynamics were statistically insignificant. By the 30th day of observation, significant positive dynamics of NT, XI, and LWES were noted, compared with the state before the start of treatment and 14 days of therapy. Despite the almost complete relief of symptoms and signs of allergy and ocular surface condition improvement, by 30 days of observation, the magnitudes of NT, XI and LWES still did not reach the normal state, which determined the need for further artificial tear therapy, eyelid hygiene and acaricide treatment. Conclusion: Combined therapy, including 0.2 % olopatadin instillation, demonstrated high efficacy in relieving symptoms (itching, tearing) and signs (hyperemia and follicular conjunctival reaction) of allergic conjunctivitis, as well as a good safety profile." @default.
• W2978346064 created "2019-10-10" @default.
• W2978346064 creator A5032057476 @default.
• W2978346064 creator A5047390900 @default.
• W2978346064 creator A5055362298 @default.
• W2978346064 creator A5084181773 @default.
• W2978346064 date "2019-10-02" @default.
• W2978346064 modified "2023-09-25" @default.
• W2978346064 title "Clinical Experience of Using 0.2 % Olopatadin in the Allergic Conjunctivitis Treatment" @default.
• W2978346064 cites W1970613833 @default.
• W2978346064 cites W1974968812 @default.
• W2978346064 cites W1981528056 @default.
• W2978346064 cites W2015424039 @default.
• W2978346064 cites W2066324007 @default.
• W2978346064 cites W2080839328 @default.
• W2978346064 cites W2333235068 @default.
• W2978346064 cites W2468865563 @default.
• W2978346064 cites W2743670010 @default.
• W2978346064 cites W2904867640 @default.
• W2978346064 doi "https://doi.org/10.18008/1816-5095-2019-3-378-385" @default.
• W2978346064 hasPublicationYear "2019" @default.
• W2978346064 type Work @default.
• W2978346064 sameAs 2978346064 @default.
• W2978346064 citedByCount "1" @default.
• W2978346064 countsByYear W29783460642021 @default.
• W2978346064 crossrefType "journal-article" @default.
• W2978346064 hasAuthorship W2978346064A5032057476 @default.
• W2978346064 hasAuthorship W2978346064A5047390900 @default.
• W2978346064 hasAuthorship W2978346064A5055362298 @default.
• W2978346064 hasAuthorship W2978346064A5084181773 @default.
• W2978346064 hasBestOaLocation W29783460641 @default.
• W2978346064 hasConcept C118487528 @default.
• W2978346064 hasConcept C141071460 @default.
• W2978346064 hasConcept C16005928 @default.
• W2978346064 hasConcept C2780238520 @default.
• W2978346064 hasConcept C2781302119 @default.
• W2978346064 hasConcept C71924100 @default.
• W2978346064 hasConceptScore W2978346064C118487528 @default.
• W2978346064 hasConceptScore W2978346064C141071460 @default.
• W2978346064 hasConceptScore W2978346064C16005928 @default.
• W2978346064 hasConceptScore W2978346064C2780238520 @default.
• W2978346064 hasConceptScore W2978346064C2781302119 @default.
• W2978346064 hasConceptScore W2978346064C71924100 @default.
• W2978346064 hasLocation W29783460641 @default.
• W2978346064 hasOpenAccess W2978346064 @default.
• W2978346064 hasPrimaryLocation W29783460641 @default.
• W2978346064 hasRelatedWork W1974319067 @default.
• W2978346064 hasRelatedWork W2045772295 @default.
• W2978346064 hasRelatedWork W2055488326 @default.
• W2978346064 hasRelatedWork W2072467851 @default.
• W2978346064 hasRelatedWork W2074056511 @default.
• W2978346064 hasRelatedWork W2200887429 @default.
• W2978346064 hasRelatedWork W2361852967 @default.
• W2978346064 hasRelatedWork W2364155931 @default.
• W2978346064 hasRelatedWork W2381384129 @default.
• W2978346064 hasRelatedWork W23836869 @default.
• W2978346064 hasRelatedWork W2384450042 @default.
• W2978346064 hasRelatedWork W2414742216 @default.
• W2978346064 hasRelatedWork W2428222290 @default.
• W2978346064 hasRelatedWork W2441308855 @default.
• W2978346064 hasRelatedWork W2783341080 @default.
• W2978346064 hasRelatedWork W2894469259 @default.
• W2978346064 hasRelatedWork W2985613474 @default.
• W2978346064 hasRelatedWork W3031582994 @default.
• W2978346064 hasRelatedWork W3032105565 @default.
• W2978346064 hasRelatedWork W3119442736 @default.
• W2978346064 isParatext "false" @default.
• W2978346064 isRetracted "false" @default.
• W2978346064 magId "2978346064" @default.
• W2978346064 workType "article" @default.